Breast Cancer Can Outsmart Treatment. Scientists May Know How to Stop It

Résumé détaillé
Researchers were surprised by the strongest responses in breast cancer models that more closely mimic human disease.
Cancer cells have a frustrating ability to adapt when treatment tries to kill them.
Now, researchers have identified a drug combination that could potentially exploit the very survival mechanisms tumors develop to escape therapy.
In a new study, published in Cancer Research, researchers at The University of Texas MD Anderson Cancer Center investigated how breast cancer cells change under prolonged treatment pressure, with the aim of finding vulnerabilities that emerge as the cells become resistant.
Their approach identified two targets, PARP and SHP2, and blocking both produced particularly striking results in preclinical models, including near-complete tumor regression in one breast cancer model.
"What surprised us most was the strongest responses in breast cancer models with intact immune systems, which more closely mimic human disease," co-author Anil Korkut, Ph.D., associate professor of Bioinformatics and Computational Biology, told Newsweek.
"We believe SHP2 inhibition creates stress in cancer cells leading to DNA damage, making them more vulnerable to targeting DNA repair proteins such as PARP," he said.
The researchers used a computational method called TargetScore to analyze changes in proteins and signaling networks as cancer cells adapted to treatment.
Unlike approaches that primarily look for genetic mutations already present in tumors, TargetScore was designed to identify biological changes that appear in response to therapy.
The team focused on resistance to inhibitors of MCL1, a protein that helps cancer cells avoid programmed cell death or apoptosis.
Début de l'article, extrait de Newsweek. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.newsweek.com)




